Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2025-10-22 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
TEZSPIRE APPROVED IN EU FOR CRSWNP
Foreign Filer Report
2025-10-22 English
Tezspire Approved in EU for CRSwNP
Regulatory Filings Classification · 1% confidence The document is a press release from AstraZeneca announcing the European Union approval of the drug 'Tezspire' for a specific medical condition. It follows the standard format of a corporate regulatory announcement (RNS - Regulatory News Service), providing details on the approval, clinical trial results (WAYPOINT), and background information on the drug and collaboration. It does not fit into specific financial reporting categories like 10-K or IR, and it is not a simple report publication announcement as it contains the substantive news itself. Therefore, it is classified as a general regulatory filing.
2025-10-22 English
US FDA APPROVES TEZSPIRE IN CRSWNP
Foreign Filer Report
2025-10-20 English
POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO
Foreign Filer Report
2025-10-20 English
US FDA Approves Tezspire in CRSwNP
Regulatory Filings Classification · 1% confidence The document is a press release from AstraZeneca announcing the FDA approval of their drug 'Tezspire' for a new indication (chronic rhinosinusitis with nasal polyps). It follows the standard format of a corporate regulatory announcement (RNS), detailing the clinical trial results, management quotes, and background information on the drug. Since it is a general regulatory announcement regarding company product developments that does not fit into specific financial reporting categories like 10-K or IR, it is classified as a Regulatory Filing (RNS).
2025-10-20 English
Positive CHMP opinion for subcutaneous Saphnelo
Regulatory Filings Classification · 1% confidence The document is a press release from AstraZeneca announcing a positive recommendation from the CHMP for the subcutaneous administration of Saphnelo in the EU. It follows the standard format of a corporate press release, detailing clinical trial results (TULIP-SC), regulatory status, and management commentary. It does not constitute a full financial report, audit, or proxy statement. As it is a general regulatory announcement regarding product development and regulatory milestones, it falls under the RNS (Regulatory Filings) category.
2025-10-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.